The world’s most trusted source of chemistry information, CAS, kicks off a major biology expansion


CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique data collection and biosequence capabilities

Columbus, Ohio, February 1, 2022 /PRNewswire/ — CAS, a division of the American Chemical Society specializing in scientific information solutions, announces the launch of a major expansion of the CAS SciFinder discovery platform into the life sciences. The enhanced platform includes over 2 million modified biosequences, 60 years of patent literature, and one of the largest collections of journal information, including biomedical and life science data from PubMed.

“The past decade has shown tremendous progress in biologic drug discovery. Research in oncology and inflammatory diseases is very promising, and more recently we have seen the first approved mRNA vaccines for COVID-19. As R&D increasingly relies on high-quality data to accelerate discovery, a major challenge facing biomedical researchers is to mine large amounts of sequence data spread across thousands of sources,” says Dr. CAS President Manuel Guzman. “This significant expansion of the CAS SciFinder discovery platform underscores our commitment to the life sciences by providing molecular biology researchers with the high-quality information that chemists have relied on on CAS for the past 110 years.”

The CAS SciFinder discovery platform extension unlocks human-indexed information from journals and patents in more than 50 languages ​​dating back to 1957 and 70 million biosequences curated by CAS scientists. The collection also includes unique biosequences not found elsewhere in electronic resources.

“We are excited to bring this enhanced collection of content to molecular biologists along with the powerful search and data visualization capabilities that SciFinder has long been known for,” said CAS Chief Product Officer. Tim Wahlberg. “This is an important step forward for our work in the life sciences and is designed specifically to solve the problems researchers face every day.”

The launch is the culmination of an 18-month effort to curate over 600 million additional proteins and nucleotides and integrate BLAST (Basic Local Alignment Search Tool), CDR (Complementarity-Determining Regions) for antibody receptors and cell counts, and the pattern-finding capabilities in the platform.

“Creating a unique platform that integrates biosequence and small molecule research meant bringing together the best scientific and technical minds available. We took what we call a ‘synthetic-organic’ approach which we believe improves the scientific workflow considerably, especially if you start a research journey from a sequence,” says CAS Product Management Director Adam Sanford. “Our goal was to create the most meaningful and intuitive user experience possible, while allowing molecular biologists to collaborate seamlessly with chemists. The result is a platform designed by scientists for scientists, which we consider to be a powerful element in drug discovery.

The enhanced SciFinder Discovery Platform is available now.

About CAS: CAS is a leader in scientific information solutions, partnering with innovators around the world to accelerate scientific breakthroughs. CAS employs more than 1,400 experts who organize, connect and analyze scientific knowledge to reveal invisible connections. For more than 100 years, scientists, patent professionals and business leaders have relied on CAS solutions and expertise to provide the perspective, insight and foresight they need to draw on the lessons of the past to discover a better future. CAS is a division of the American Chemical Society. Connect with us at

About CAS SciFinder Discovery Platform™: CAS SciFinder Discovery Platform leverages the world’s largest organized source of scientific information, bringing together task-specific solutions including CAS SciFindernot, CAS Formulas® and CAS Analytical Methods™. The CAS SciFinder discovery platform supports multi-faceted scientific research such as retrosynthetic planning, formulation design, test-related method research, and biosequence research to accelerate breakthroughs at every stage of the discovery journey. ‘innovation. Learn more at

Contact: Tina Tomeo, [email protected]+1 614.447.3731

Logo –



Comments are closed.